The DG75 B-cell lymphoma line exhibits biclonal immunoglobulin gene rearrangement

Qi,Zongli; Li,Yuan; Hu,Jun; Guo,Hua; Zhao,Xiangrong; Wang,Guanghua; Gao,Jinwei; Hu,Qiaoxia

doi:10.3892/br.2012.22

The DG75 B-cell lymphoma line exhibits biclonal immunoglobulin gene rearrangement

Authors:
- Zongli Qi
- Yuan Li
- Jun Hu
- Hua Guo
- Xiangrong Zhao
- Guanghua Wang
- Jinwei Gao
- Qiaoxia Hu
View Affiliations

Affiliations: Laboratory Center, Shaanxi Provincial People's Hospital and The Third Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710068, P.R. China
Published online on: October 15, 2012 https://doi.org/10.3892/br.2012.22
Pages: 115-118

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangement (GR) studies have been successfully employed to investigate the clonality and cell lineage of various lymphoid malignancies. Several lymphoma cell lines, such as BJAB, RAJI, DG75 and Jurkat cell lines, were often used as the positive controls in GR detection assays. Of those, the DG75 B-cell lymphoma line was found to exhibit biclonality [two or more homoduplex and heteroduplex bands in a polymerase chain reaction (PCR) product of clonality assay] in the PCR of GR detection assays. To further explore these characteristics of the biclonal phenomenon, the PCR products were purified and cloned into a pEGM-T clone vector. The sequences were analyzed using DNA analysis software. The results demonstrated that the two bands originated from two forms of GR of DG75 cell lines, i.e., DG75 is a biclonal cell line in Ig GRs, which has not been reported before.

View Figures

View References

1.	Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martinez-Brü C and Grubb A: Cystatin C as a marker of GFR - history, indications, and future research. Clin Biochem. 38:1–8. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Newman DJ: Cystatin C. Ann Clin Biochem. 39:89–104. 2002. View Article : Google Scholar
3.	Chew JS, Saleem M, Florkowski CM and George PM: Cystatin C - a paradigm of evidence based laboratory medicine. Clin Biochem Rev. 29:47–62. 2008.PubMed/NCBI
4.	Ando N, Iizuka T, Ide H, et al: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol. 21:4592–4596. 2003. View Article : Google Scholar : PubMed/NCBI
5.	Ando N, Kato H, Igaki H, et al: A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar
6.	American Society of Clinical Oncology; Kris MG, Hesketh PJ, Somerfield MR, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 24:2932–2947. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Kume M, Yasui H, Yoshikawa Y, et al: Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients. Cancer Chemother Pharmacol. 69:1537–1544. 2012. View Article : Google Scholar
8.	Miki I, Tamura T, Nakamura T, et al: Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma. Ther Drug Monit. 27:369–374. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Nakade S, Ohno T, Kitagawa J, et al: Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol. 63:75–83. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Takara K, Fujita M, Minegaki T, et al: Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells. Eur J Pharm Sci. 45:272–281. 2012. View Article : Google Scholar : PubMed/NCBI
11.	Bjarnadóttir M, Grubb A and Olafsson I: Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest. 55:617–623. 1995.PubMed/NCBI
12.	Zhang C, Beckermann B, Kallifatidis G, et al: Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. Int J Oncol. 29:1295–1301. 2006.
13.	Abrahamson M, Olafsson I, Palsdottir A, et al: Structure and expression of the human cystatin C gene. Biochem J. 268:287–294. 1990.PubMed/NCBI
14.	Abrahamson M, Barrett AJ, Salvesen G and Grubb A: Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J Biol Chem. 261:11282–11289. 1986.
15.	Grzonka Z, Jankowska E, Kasprzykowski F, et al: Structural studies of cysteine proteases and their inhibitors. Acta Biochim Pol. 48:1–20. 2001.PubMed/NCBI
16.	Bijnsdorp IV, Peters GJ, Temmink OH, Fukushima M and Kruyt FA: Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer. 126:2457–2468. 2010.
17.	Mathew R, Karantza-Wadsworth V and White E: Role of autophagy in cancer. Nat Rev Cancer. 7:961–967. 2007. View Article : Google Scholar
18.	Tizon B, Sahoo S, Yu H, et al: Induction of autophagy by cystatin C: a mechanism that protects murine primary cortical neurons and neuronal cell lines. PLoS One. 5:e98192010. View Article : Google Scholar : PubMed/NCBI
19.	O’Donovan TR, O’Sullivan GC and McKenna SL: Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy. 7:509–524. 2011.
20.	Balsalobre A, Brown SA, Marcacci L, et al: Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science. 289:2344–2347. 2000. View Article : Google Scholar : PubMed/NCBI
21.	Terazono H, Hamdan A, Matsunaga N, et al: Modulatory effects of 5-fluorouracil on the rhythmic expression of circadian clock genes: a possible mechanism of chemotherapy-induced circadian rhythm disturbances. Biochem Pharmacol. 75:1616–1622. 2008. View Article : Google Scholar